阿奇霉素联合复方异丙托溴铵雾化吸入治疗小儿支原体肺炎的临床疗效

Clinical Efficacy of Azithromycin Plus Combined Nebulized Ipratropium Bromide in Children with Mycoplasma Pneumoniae

目的 支原体肺炎儿童好发,治疗不及时可能给患儿生长发育带来严重影响,本研究旨在探讨阿奇霉素联合复方异丙托溴铵雾化吸入治疗小儿支原体肺炎的临床疗效和不良反应发生情况。方法 选取2018年2月-2019年5月于深圳市龙岗区第二人民医院儿科接受治疗的支原体肺炎患儿106例,按照随机数字表法将所有患儿分为观察组(53例)和对照组(53例),对照组患者予以阿奇霉素治疗,观察组患者在对照组患者治疗的基础上联合复方异丙托溴铵雾化吸入治疗。比较两组患儿临床疗效、康复进程、气道功能指标以及不良反应发生情况。结果 治疗后,观察组患者临床治疗有效率显著高于对照组的,两组对比差异存在统计学意义(P <0.05)。治疗前,两组间住院、咳嗽、肺部啰音消失、肺部阴影消失、胸闷时间比较,差异无统计学意义(P>0.05);治疗后,观察组患儿住院时间及上述症状持续时间均短于对照组(P <0.05)。治疗前,两组间MEF25、MEF50、MEF25~75水平比较(P>0.05);治疗后,观察组患儿上述指标水平显著高于对照组(P <0.05)。治疗期间,观察组患儿不良反应总发生率与对照组比较,差异无统计学意义(P>0.05)。结论 阿奇霉素联合复方异丙托溴铵雾化吸入治疗小儿支原体肺炎相比于单用阿奇霉素可有效提高临床疗效,减少住院时间,值得在临床上大力推广应用。

Objective Children with mycoplasma pneumonia have a high incidence, and the timely treatment may cause severe effects on the growth and development of children, this study aimed to investigate the clinical efficacy and adverse event occurrence of Azithromycin combined with a compound nebulized ipratropium bromide for the treatment of mycoplasma pneumonia in children.Methods A total of 106 children with mycoplasma pneumonia who were treated in the Department of Pediatrics of our hospital from February 2018 to may 2019 were selected, and all the children were divided into observation group(n =53) and control group(n =53) according to the random number table method, the control group patients were treated with azithromycin, and the observation group patients were treated with combined therapy of combined nebulized ipratropium bromide inhalation on the basis of the control group patients’ treatment.The clinical outcomes, rehabilitation progress, airway function indexes as well as the occurrence of adverse effects were compared between the two groups.Results After treatment, the clinical treatment response rate of patients in the observation group(92.45%)was significantly higher(79.25%) than that of the control group, with a statistical difference(P <0.05).Before treatment, duration of hospitalization, cough, disappearance of pulmonary rales, disappearance of pulmonary shadow, and chest tightness were compared between the two groups(P >0.05);However,after treatment, the duration of hospitalization and the duration of the above symptoms in children in the observation group were shorter than those in the control group(P <0.05).Before treatment, MEF 25, MEF 50, and MEF 25 to 75 levels were compared between the two groups(P >0.05);After treatment,children in the observation group had significantly higher levels of the above indicators than those in the control group(P <0.05).During treatment, the overall incidence of adverse effects among children in the observation group(7.55%) was not statistically different from that(9.43%) in the control group(P >0.05).Conclusion Azithromycin combined with the aerosolization of the compound ipratropium bromide for the treatment of Mycoplasma pneumoniae in children can effectively improve the clinical efficacy and reduce the length of hospital stay compared with azithromycin alone, which deserves to be greatly promoted in the clinic.